ReP USP - Resultado da busca

Artigo de periodico
Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: insights from the TREAT trial (2022)
Cantor, Warren J; Tan, Mary; Berwanger, Otavio; Lavi, Shahar; White, Harvey D; Nicolau, Jose Carlos ; Dehghani, Payam; Tajer, Carlos D; Lopes, Renato D; Moia, Diogo D. F
Source: American heart journal. Unidade: FM
Subjects: MORFINA, INFARTO DO MIOCÁRDIO, FÁRMACOS SINTÉTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CANTOR, Warren J et al. Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: insights from the TREAT trial. American heart journal, v. 251, p. 1-12, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2022.05.005. Acesso em: 14 nov. 2024.
APA
Cantor, W. J., Tan, M., Berwanger, O., Lavi, S., White, H. D., Nicolau, J. C., et al. (2022). Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: insights from the TREAT trial. American heart journal, 251, 1-12. doi:10.1016/j.ahj.2022.05.005
NLM
Cantor WJ, Tan M, Berwanger O, Lavi S, White HD, Nicolau JC, Dehghani P, Tajer CD, Lopes RD, Moia DDF. Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: insights from the TREAT trial [Internet]. American heart journal. 2022 ; 251 1-12.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.ahj.2022.05.005
Vancouver
Cantor WJ, Tan M, Berwanger O, Lavi S, White HD, Nicolau JC, Dehghani P, Tajer CD, Lopes RD, Moia DDF. Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: insights from the TREAT trial [Internet]. American heart journal. 2022 ; 251 1-12.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.ahj.2022.05.005
Artigo de periodico
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial (2022)
Heerspink, Hiddo J. L; Sjostrom, C. David; Jongs, Niels; Chertow, Glenn M; Kosiborod, Mikhail; Hou, Fan Fan; McMurray, John J; Rossing, Peter; Correa-Rotter, Ricardo; Kurlyandskaya, Raisa; Noronha, Irene de Lourdes
Source: European heart journal. Unidade: FM
Subjects: DOENÇA CRÔNICA, INSUFICIÊNCIA RENAL, MORTALIDADE, ESTUDOS RANDOMIZADOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEERSPINK, Hiddo J. L et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. European heart journal, v. 42, n. 13, p. 1216-1227, 2022Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehab094. Acesso em: 14 nov. 2024.
APA
Heerspink, H. J. L., Sjostrom, C. D., Jongs, N., Chertow, G. M., Kosiborod, M., Hou, F. F., et al. (2022). Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. European heart journal, 42( 13), 1216-1227. doi:10.1093/eurheartj/ehab094
NLM
Heerspink HJL, Sjostrom CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJ, Rossing P, Correa-Rotter R, Kurlyandskaya R, Noronha I de L. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial [Internet]. European heart journal. 2022 ; 42( 13): 1216-1227.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1093/eurheartj/ehab094
Vancouver
Heerspink HJL, Sjostrom CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJ, Rossing P, Correa-Rotter R, Kurlyandskaya R, Noronha I de L. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial [Internet]. European heart journal. 2022 ; 42( 13): 1216-1227.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1093/eurheartj/ehab094
Artigo de periodico
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial (2022)
Berg, David D.; Docherty, Kieran F.; Sattar, Naveed; Jarolim, Petr; Welsh, Paul; Jhund, Pardeep S.; Anand, Inder S.; Chopra, Vijay; Boer, Rudolf A. de; Kosiborod, Mikhail N.; Nicolau, Jose Carlos
Source: Circulation. Conference titles: Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, VENTRÍCULO CARDÍACO, MODELOS DE RISCOS PROPORCIONAIS, IDOSOS, ENSAIO CLÍNICO, GLICOSÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERG, David D. et al. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, v. 145, n. 3, p. 158-169, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.121.057852. Acesso em: 14 nov. 2024.
APA
Berg, D. D., Docherty, K. F., Sattar, N., Jarolim, P., Welsh, P., Jhund, P. S., et al. (2022). Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, 145( 3), 158-169. doi:10.1161/CIRCULATIONAHA.121.057852
NLM
Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, Boer RA de, Kosiborod MN, Nicolau JC. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial [Internet]. Circulation. 2022 ; 145( 3): 158-169.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.057852
Vancouver
Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, Boer RA de, Kosiborod MN, Nicolau JC. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial [Internet]. Circulation. 2022 ; 145( 3): 158-169.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.057852
Artigo de periodico
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial (2022)
Furtado, Remo H. M.; Raz, Itamar; Goodrich, Erica L.; Murphy, Sabina A.; Bhatt, Deepak L.; Leiter, Lawrence A.; Mcguire, Darren K.; Wilding, John P. H.; Aylward, Philip; Dalby, Anthony J.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: HIPERTENSÃO, INSUFICIÊNCIA CARDÍACA, DIABETES MELLITUS, RESULTADO DE TRATAMENTO, FÁRMACOS (SISTEMA CARDIOVASCULAR)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M. et al. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, v. 145, n. 21, p. 1581-1591, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.121.058103. Acesso em: 14 nov. 2024.
APA
Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 145( 21), 1581-1591. doi:10.1161/CIRCULATIONAHA.121.058103
NLM
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103
Vancouver
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103
Artigo de periodico-carta/editorial
Systemic blood pressure in heart failure the next frontier in prognosis and chronic HF treatment?. [Editorial] (2022)
Bocchi, Edimar Alcides ; Ventura, Hector O
Source: Jacc-heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, SOBREVIDA, HIPERTENSÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCHI, Edimar Alcides e VENTURA, Hector O. Systemic blood pressure in heart failure the next frontier in prognosis and chronic HF treatment? [Editorial]. Jacc-heart failure. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jchf.2022.02.017. Acesso em: 14 nov. 2024. , 2022
APA
Bocchi, E. A., & Ventura, H. O. (2022). Systemic blood pressure in heart failure the next frontier in prognosis and chronic HF treatment? [Editorial]. Jacc-heart failure. Oxford: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.jchf.2022.02.017
NLM
Bocchi EA, Ventura HO. Systemic blood pressure in heart failure the next frontier in prognosis and chronic HF treatment? [Editorial] [Internet]. Jacc-heart failure. 2022 ; 10( 6): 393-396.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jchf.2022.02.017
Vancouver
Bocchi EA, Ventura HO. Systemic blood pressure in heart failure the next frontier in prognosis and chronic HF treatment? [Editorial] [Internet]. Jacc-heart failure. 2022 ; 10( 6): 393-396.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jchf.2022.02.017
Artigo de periodico
The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? (2022)
Bocchi, Edimar Alcides ; Lima, Ivna Girard Cunha Vieira
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: RESULTADO DE TRATAMENTO, INSUFICIÊNCIA CARDÍACA, FÁRMACOS SINTÉTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCHI, Edimar Alcides e LIMA, Ivna Girard Cunha Vieira. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis?. Journal of the american college of cardiology, v. 80, n. 6, p. 595-597, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50443. Acesso em: 14 nov. 2024.
APA
Bocchi, E. A., & Lima, I. G. C. V. (2022). The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? Journal of the american college of cardiology, 80( 6), 595-597. doi:10.1016/j.jacc.2022.05.028
NLM
Bocchi EA, Lima IGCV. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? [Internet]. Journal of the american college of cardiology. 2022 ; 80( 6): 595-597.[citado 2024 nov. 14 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50443
Vancouver
Bocchi EA, Lima IGCV. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? [Internet]. Journal of the american college of cardiology. 2022 ; 80( 6): 595-597.[citado 2024 nov. 14 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50443
Artigo de periodico
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF (2022)
Butt, Jawad H.; Docherty, Kieran F.; Jhund, Pardeep S.; Boer, Rudolf A.; Bohm, Michael; Desai, Akshay S.; Howlett, Jonathan G.; Inzucchi, Silvio E.; Kosiborod, Mikhail N.; Martinez, Felipe A.; Nicolau, Jose Carlos
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, FIBRILAÇÃO ATRIAL, GLICOSÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUTT, Jawad H. et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European journal of heart failure, v. 24, n. 3, p. 513-525, 2022Tradução . . Disponível em: https://doi.org/10.1002/ejhf.2381. Acesso em: 14 nov. 2024.
APA
Butt, J. H., Docherty, K. F., Jhund, P. S., Boer, R. A., Bohm, M., Desai, A. S., et al. (2022). Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European journal of heart failure, 24( 3), 513-525. doi:10.1002/ejhf.2381
NLM
Butt JH, Docherty KF, Jhund PS, Boer RA, Bohm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF [Internet]. European journal of heart failure. 2022 ; 24( 3): 513-525.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1002/ejhf.2381
Vancouver
Butt JH, Docherty KF, Jhund PS, Boer RA, Bohm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF [Internet]. European journal of heart failure. 2022 ; 24( 3): 513-525.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1002/ejhf.2381
Artigo de periodico
Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial (2019)
Berwanger, Otavio; Lopes, Renato D; Moia, Diogo D. F; Fonseca, Francisco A; Jiang, Lixin; Goodman, Shaun G; Nicholls, Stephen J; Parkhomenko, Alexander; Averkov, Oleg; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: FIBRINÓLISE, AGREGAÇÃO PLAQUETÁRIA, INFARTO DO MIOCÁRDIO, DOENÇAS CARDIOVASCULARES, ACIDENTE VASCULAR CEREBRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERWANGER, Otavio et al. Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial. Journal of the american college of cardiology, v. 73, n. 22, p. 2819-2828, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.03.011. Acesso em: 14 nov. 2024.
APA
Berwanger, O., Lopes, R. D., Moia, D. D. F., Fonseca, F. A., Jiang, L., Goodman, S. G., et al. (2019). Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial. Journal of the american college of cardiology, 73( 22), 2819-2828. doi:10.1016/j.jacc.2019.03.011
NLM
Berwanger O, Lopes RD, Moia DDF, Fonseca FA, Jiang L, Goodman SG, Nicholls SJ, Parkhomenko A, Averkov O, Nicolau JC. Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 22): 2819-2828.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jacc.2019.03.011
Vancouver
Berwanger O, Lopes RD, Moia DDF, Fonseca FA, Jiang L, Goodman SG, Nicholls SJ, Parkhomenko A, Averkov O, Nicolau JC. Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 22): 2819-2828.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jacc.2019.03.011
Artigo de periodico
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial (2019)
Furtado, Remo H. M; Bonaca, Marc P; Raz, Itamar; Zelniker, Thomas A; Mosenzon, Ofri; Cahn, Avivit; Kuder, Julia; Murphy, Sabina A; Bhatt, Deepak L; Nicolau, José Carlos
Source: Circulation. Unidade: FM
Subjects: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, INFARTO DO MIOCÁRDIO, ANTIDIABÉTICOS (HIPOGLICEMIANTES), RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial. Circulation, v. 139, n. 22, p. 2516-2527, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.039996. Acesso em: 14 nov. 2024.
APA
Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., et al. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial. Circulation, 139( 22), 2516-2527. doi:10.1161/CIRCULATIONAHA.119.039996
NLM
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Nicolau JC. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial [Internet]. Circulation. 2019 ; 139( 22): 2516-2527.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.039996
Vancouver
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Nicolau JC. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial [Internet]. Circulation. 2019 ; 139( 22): 2516-2527.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.039996
Artigo de periodico
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study (2019)
Bhatt, Deepak L; Fox, Kim; Harrington, Robert A; Leiter, Lawrence A; Mehta, Shamir R; Simon, Tabassome; Andersson, Marielle; Himmelmann, Anders; Ridderstrale, Wilhelm; Nicolau, José Carlos
Source: Clinical cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DIABETES MELLITUS, VASOS CORONÁRIOS, PACIENTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BHATT, Deepak L et al. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical cardiology, v. 42, n. 5, p. 498-505, 2019Tradução . . Disponível em: https://doi.org/10.1002/clc.23164. Acesso em: 14 nov. 2024.
APA
Bhatt, D. L., Fox, K., Harrington, R. A., Leiter, L. A., Mehta, S. R., Simon, T., et al. (2019). Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical cardiology, 42( 5), 498-505. doi:10.1002/clc.23164
NLM
Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstrale W, Nicolau JC. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study [Internet]. Clinical cardiology. 2019 ; 42( 5): 498-505.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1002/clc.23164
Vancouver
Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstrale W, Nicolau JC. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study [Internet]. Clinical cardiology. 2019 ; 42( 5): 498-505.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1002/clc.23164
Artigo de periodico
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes (2018)
Everett, Brendan M.; Nicolau, Jose C.; DONATH, Marc Y.; PRADHAN, Aruna D.; THUREN, Tom; PAIS, Prem; GLYNN, Robert J; LIBBY, Peter; RIDKER, Paul M.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTI-INFLAMATÓRIOS, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 14 nov. 2024.
APA
Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
NLM
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Vancouver
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Artigo de periodico
Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction a randomized clinical trial (2018)
Berwanger, Otavio; Nicolau, Jose C
Source: Jama cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, ESTUDOS RANDOMIZADOS, FÁRMACOS (SISTEMA CARDIOVASCULAR), INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERWANGER, Otavio e NICOLAU, Jose C. Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction a randomized clinical trial. Jama cardiology, v. 3, n. 5, p. 391-399, 2018Tradução . . Disponível em: https://doi.org/10.1001/jamacardio.2018.0612. Acesso em: 14 nov. 2024.
APA
Berwanger, O., & Nicolau, J. C. (2018). Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction a randomized clinical trial. Jama cardiology, 3( 5), 391-399. doi:10.1001/jamacardio.2018.0612
NLM
Berwanger O, Nicolau JC. Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction a randomized clinical trial [Internet]. Jama cardiology. 2018 ; 3( 5): 391-399.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1001/jamacardio.2018.0612
Vancouver
Berwanger O, Nicolau JC. Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction a randomized clinical trial [Internet]. Jama cardiology. 2018 ; 3( 5): 391-399.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1001/jamacardio.2018.0612
Artigo de periodico
Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial (2018)
Corbalan, Ramon; Nicolau, Jose Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTICOAGULANTES, FIBRILAÇÃO ATRIAL, ACIDENTE VASCULAR CEREBRAL, AMÉRICA LATINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CORBALAN, Ramon e NICOLAU, Jose Carlos. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial. Journal of the american college of cardiology, v. 72, n. 13, p. 1466-1475, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.07.037. Acesso em: 14 nov. 2024.
APA
Corbalan, R., & Nicolau, J. C. (2018). Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial. Journal of the american college of cardiology, 72( 13), 1466-1475. doi:10.1016/j.jacc.2018.07.037
NLM
Corbalan R, Nicolau JC. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 13): 1466-1475.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.037
Vancouver
Corbalan R, Nicolau JC. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 13): 1466-1475.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.037
Artigo de periodico
Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study (2018)
Al-zakwani, Ibrahim; Santos Filho, Raul Dias dos
Source: Lipids in health and disease. Unidade: FM
Subjects: DIABETES MELLITUS, HIPERCOLESTEROLEMIA, ARÁBIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AL-ZAKWANI, Ibrahim e SANTOS FILHO, Raul Dias dos. Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study. Lipids in health and disease, v. 17, 2018Tradução . . Disponível em: https://doi.org/10.1186/s12944-018-0667-y. Acesso em: 14 nov. 2024.
APA
Al-zakwani, I., & Santos Filho, R. D. dos. (2018). Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study. Lipids in health and disease, 17. doi:10.1186/s12944-018-0667-y
NLM
Al-zakwani I, Santos Filho RD dos. Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study [Internet]. Lipids in health and disease. 2018 ; 17[citado 2024 nov. 14 ] Available from: https://doi.org/10.1186/s12944-018-0667-y
Vancouver
Al-zakwani I, Santos Filho RD dos. Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study [Internet]. Lipids in health and disease. 2018 ; 17[citado 2024 nov. 14 ] Available from: https://doi.org/10.1186/s12944-018-0667-y
Artigo de periodico
Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians (2018)
Miskowiak, K. W.; Lafer, B.
Source: Bipolar disorders. Unidade: FM
Subjects: COGNIÇÃO, ESTUDOS RANDOMIZADOS, MEMÓRIA, TRANSTORNO BIPOLAR, TESTES NEUROPSICOLÓGICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MISKOWIAK, K. W. e LAFER, B. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. Bipolar disorders, v. 20, n. 3, p. 184-194, 2018Tradução . . Disponível em: https://doi.org/10.1111/bdi.12595. Acesso em: 14 nov. 2024.
APA
Miskowiak, K. W., & Lafer, B. (2018). Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. Bipolar disorders, 20( 3), 184-194. doi:10.1111/bdi.12595
NLM
Miskowiak KW, Lafer B. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians [Internet]. Bipolar disorders. 2018 ; 20( 3): 184-194.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1111/bdi.12595
Vancouver
Miskowiak KW, Lafer B. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians [Internet]. Bipolar disorders. 2018 ; 20( 3): 184-194.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1111/bdi.12595
Artigo de periodico
Pulmonary arterialhHypertension-related morbidity is prognostic for mortality (2018)
Mclaughlin, Vallerie V.; Souza, Rogerio
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERTENSÃO PULMONAR, MORBIDADE, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MCLAUGHLIN, Vallerie V. e SOUZA, Rogerio. Pulmonary arterialhHypertension-related morbidity is prognostic for mortality. Journal of the american college of cardiology, v. 71, n. 7, p. 752-763, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2017.12.010. Acesso em: 14 nov. 2024.
APA
Mclaughlin, V. V., & Souza, R. (2018). Pulmonary arterialhHypertension-related morbidity is prognostic for mortality. Journal of the american college of cardiology, 71( 7), 752-763. doi:10.1016/j.jacc.2017.12.010
NLM
Mclaughlin VV, Souza R. Pulmonary arterialhHypertension-related morbidity is prognostic for mortality [Internet]. Journal of the american college of cardiology. 2018 ; 71( 7): 752-763.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jacc.2017.12.010
Vancouver
Mclaughlin VV, Souza R. Pulmonary arterialhHypertension-related morbidity is prognostic for mortality [Internet]. Journal of the american college of cardiology. 2018 ; 71( 7): 752-763.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jacc.2017.12.010
Artigo de periodico
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract (2018)
Mach, Francois; Santos, Raul D
Source: European heart journal. Unidade: FM
Subjects: INSUFICIÊNCIA RENAL CRÔNICA, MORTALIDADE, DIABETES MELLITUS, ESTUDOS RANDOMIZADOS, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACH, Francois e SANTOS, Raul D. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European heart journal, v. 39, n. 27, p. 2526-+, 2018Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehy182. Acesso em: 14 nov. 2024.
APA
Mach, F., & Santos, R. D. (2018). Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European heart journal, 39( 27), 2526-+. doi:10.1093/eurheartj/ehy182
NLM
Mach F, Santos RD. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract [Internet]. European heart journal. 2018 ; 39( 27): 2526-+.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1093/eurheartj/ehy182
Vancouver
Mach F, Santos RD. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract [Internet]. European heart journal. 2018 ; 39( 27): 2526-+.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1093/eurheartj/ehy182
Artigo de periodico
Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf (2018)
Al-rasadi, Khalid; Santos, Raul D.
Source: Journal of clinical lipidology. Unidade: FM
Subjects: ARÁBIA, HIPERCOLESTEROLEMIA, DIABETES MELLITUS, PROGNÓSTICO, SÍNDROME CORONARIANA AGUDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AL-RASADI, Khalid e SANTOS, Raul D. Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. Journal of clinical lipidology, v. 12, n. 3, p. 685-692, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacl.2018.02.003. Acesso em: 14 nov. 2024.
APA
Al-rasadi, K., & Santos, R. D. (2018). Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. Journal of clinical lipidology, 12( 3), 685-692. doi:10.1016/j.jacl.2018.02.003
NLM
Al-rasadi K, Santos RD. Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf [Internet]. Journal of clinical lipidology. 2018 ; 12( 3): 685-692.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jacl.2018.02.003
Vancouver
Al-rasadi K, Santos RD. Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf [Internet]. Journal of clinical lipidology. 2018 ; 12( 3): 685-692.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.jacl.2018.02.003
Artigo de periodico
Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54 (2018)
Bonaca, Marc P.; Wiviott, Stephen D; Morrow, David A; Steg, P. Gabriel; Hamm, Christian; Bhatt, Deepak L; Storey, Robert F; Cohen, Marc; Kuder, Julia; Nicolau, José Carlos
Source: Journal of the american heart association. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, AGREGAÇÃO PLAQUETÁRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONACA, Marc P. et al. Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54. Journal of the american heart association, v. 7, n. 22, 2018Tradução . . Disponível em: https://doi.org/10.1161/JAHA.118.009260. Acesso em: 14 nov. 2024.
APA
Bonaca, M. P., Wiviott, S. D., Morrow, D. A., Steg, P. G., Hamm, C., Bhatt, D. L., et al. (2018). Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54. Journal of the american heart association, 7( 22). doi:10.1161/JAHA.118.009260
NLM
Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Nicolau JC. Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54 [Internet]. Journal of the american heart association. 2018 ; 7( 22):[citado 2024 nov. 14 ] Available from: https://doi.org/10.1161/JAHA.118.009260
Vancouver
Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Nicolau JC. Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54 [Internet]. Journal of the american heart association. 2018 ; 7( 22):[citado 2024 nov. 14 ] Available from: https://doi.org/10.1161/JAHA.118.009260
Artigo de periodico
Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015:: a novel analysis from the Global Burden of Disease Study 2015 (2017)
Barber, Ryan M; Benseñor, Isabela Judith Martins; Lotufo, Paulo Andrade
Source: Lancet. Unidade: FM
Subjects: MORTALIDADE, QUALIDADE DE VIDA, ATENÇÃO À SAÚDE, ÍNDICES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BARBER, Ryan M e BENSEÑOR, Isabela Judith Martins e LOTUFO, Paulo Andrade. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015:: a novel analysis from the Global Burden of Disease Study 2015. Lancet, v. 390, n. 10113, p. 2627-2642, 2017Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(17)30818-8. Acesso em: 14 nov. 2024.
APA
Barber, R. M., Benseñor, I. J. M., & Lotufo, P. A. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015:: a novel analysis from the Global Burden of Disease Study 2015. Lancet, 390( 10113), 2627-2642. doi:10.1016/S0140-6736(17)30818-8
NLM
Barber RM, Benseñor IJM, Lotufo PA. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015:: a novel analysis from the Global Burden of Disease Study 2015 [Internet]. Lancet. 2017 ; 390( 10113): 2627-2642.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/S0140-6736(17)30818-8
Vancouver
Barber RM, Benseñor IJM, Lotufo PA. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015:: a novel analysis from the Global Burden of Disease Study 2015 [Internet]. Lancet. 2017 ; 390( 10113): 2627-2642.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/S0140-6736(17)30818-8

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Source title

Funding Agencies